EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudieLeitlinie

Validation of the 2023 FIGO staging system and its concordance with the JSGO guidelines in endometrial cancer: A multi‐institutional retrospective study in Japan

Takatoshi Manabe iD, Hiroko Machida iD, Taichi Mizushima iD, Shinichi Endo iD, Jun Takeuchi iD, Koji Matsuo iD, Miwa Yasaka iD, Hiroshi Kajiwara iD, Satoshi Fujii iD, Mayu Nakagawa iD, Junki Koike iD, Motohiro Chosokabe iD und 4 weitere

Journal of Obstetrics and Gynaecology Research · 2025

DOI: 10.1111/jog.70049 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Takatoshi Manabe und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Staging, Practice Guidelines as Topic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Tokai University Research Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To validate the prognostic accuracy of the 2023 FIGO staging system and assess its alignment with the Japan Society of Gynecologic Oncology (JSGO) guidelines for endometrial cancer treatment.

Methods

This retrospective cohort study included 1207 patients with endometrial cancer treated at four academic hospitals in Kanagawa, Japan, between 2018 and 2022. Patients were reclassified according to the FIGO 2023 system and the JSGO recurrence risk categories. Primary endpoints included stage migration, recurrence risk (RR), overall survival (OS), and concordance between the two classification systems.

Results

Under FIGO 2023, the stage distribution was: I, 741 (61.4%); II, 203 (16.8%); III, 149 (12.3%); and IV, 114 (9.4%), with stage migration observed in 36.3% of cases. The FIGO 2023 system provided clearer stratification of 3‐year RR than FIGO 2009, with the RR gap widening from 80.0% to 90.1%. Sixteen patients (3.5%) with stage IA3 were classified as high risk by JSGO criteria, while 14.4% of patients considered high risk by JSGO were downstaged under FIGO 2023. Additionally, 46 patients (19.6%) with FIGO stage IA were reclassified as intermediate risk owing to focal lymphovascular space invasion (LVSI). Substantial LVSI was significantly associated with recurrence and poor prognosis (3‐year OS rates: none 94.3%, focal 89.9%, and substantial 40.7%; p < 0.05). Molecular testing was limited: p53 in 30.2%, MSI in 5.9%, and POLE was not available.

Conclusions

FIGO 2023 improves prognostic precision. Incorporating LVSI extent and molecular data may refine JSGO classifications and support more individualized adjuvant therapy strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsNeoplasm StagingPractice Guidelines as TopicHumansFemaleRetrospective StudiesJapanMiddle AgedAgedPrognosisAged, 80 and overSocieties, MedicalAdultNeoplasm Recurrence, Local

Stichwörter der Autor:innen

FIGO stagingJSGO guidelineendometrial neoplasmslymph‐vascular space invasion

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan.
  • Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
  • Department of Obstetrics and Gynecology, Kitasato University School of Medicine, Kanagawa, Japan.
  • Department of Obstetrics and Gynecology, St Marianna University School of Medicine, Kanagawa, Japan.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
  • Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.

ORCID-Profile: Takatoshi Manabe, Hiroko Machida, Taichi Mizushima, Shinichi Endo, Jun Takeuchi, Koji Matsuo, Miwa Yasaka, Hiroshi Kajiwara, Satoshi Fujii, Mayu Nakagawa, Junki Koike, Motohiro Chosokabe, Etsuko Miyagi, Kazuyoshi Kato, Nao Suzuki, Mikio Mikami

Förderung

  • Tokai University Research Organization

Zitieren

APA

Manabe, T., Machida, H., Mizushima, T., Endo, S., Takeuchi, J., Matsuo, K., Yasaka, M., Kajiwara, H., Fujii, S., Nakagawa, M., Koike, J., Chosokabe, M., Miyagi, E., Kato, K., Suzuki, N., & Mikami, M. (2025). Validation of the 2023 FIGO staging system and its concordance with the JSGO guidelines in endometrial cancer: A multi‐institutional retrospective study in Japan. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70049

Vancouver

Manabe T, Machida H, Mizushima T, Endo S, Takeuchi J, Matsuo K, et al. Validation of the 2023 FIGO staging system and its concordance with the JSGO guidelines in endometrial cancer: A multi‐institutional retrospective study in Japan. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.70049

BibTeX
@article{Manabe2025,
  author = {Manabe, Takatoshi and Machida, Hiroko and Mizushima, Taichi and Endo, Shinichi and Takeuchi, Jun and Matsuo, Koji and Yasaka, Miwa and Kajiwara, Hiroshi and Fujii, Satoshi and Nakagawa, Mayu and Koike, Junki and Chosokabe, Motohiro and Miyagi, Etsuko and Kato, Kazuyoshi and Suzuki, Nao and Mikami, Mikio},
  title = {Validation of the 2023 FIGO staging system and its concordance with the JSGO guidelines in endometrial cancer: A multi‐institutional retrospective study in Japan},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2025},
  doi = {10.1111/jog.70049}
}
Kostenlos starten →